Curis down on $15 mln at-the-market offering

Curis

06/07/2023 14:19

** Cancer drug developer Curis Inc's shares  CRIS.O  down
11.2% at $0.73 in premarket trading 
    ** Co reports direct offering of 18.4 mln shares of its
common stock at $0.82/share 
    ** CRIS plans to use proceeds from offering of about $15.1
mln, on research and development 
    ** Offering is expected to close on or about July 10
    ** Cantor Fitzgerald & Co and Truist Securities are
placement agents for the offering 
    ** Separately, CRIS also reported that U.S. Food and Drug
Administration has removed partial hold on its
early-to-mid-stage blood cancer study for experimental drug,
emavusertib 
    ** In April, FDA placed partial clinical hold on the study,
after the death of a patient 
    ** The health regulator in August notified that co may
resume enrollment of additional patients in the monotherapy dose
finding phase of the study
    ** As of Wednesday's close, stock up 49.2% this year 

 (Reporting by Pratik Jain in Bengaluru)
 ((Pratik.Jain@thomsonreuters.com;))